VRDN · Viridian Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| Fairmount Funds Management LLC Director | ▲ Buy | Open Market | 5,090,928 Shares held | 5/11/2026 | View profile |
| Frazier Life Sciences Public Fund, L.P. 10% Owner | ▲ Buy | Open Market | 1,505,200 Shares held | 9/23/2021 | View profile |
| Violin Jonathan See Remarks | ▼ Sell | Open Market | 430,905 Shares held | 2/2/2023 | View profile |
| Scott Dunseth Myers Director | ▲ Buy | Open Market | 259,500 Shares held | 4/12/2023 | View profile |
| Tripuraneni Radhika Chief Medical Officer | ▲ Buy | Option Exercise | 40,000 Shares held | 8/14/2026 | View profile |
| Mahoney Stephen F. President and CEO | ▼ Sell | Tax Withholding | 33,130 Shares held | 3/3/2026 | View profile |
| Meisner Lara Chief Legal Officer | ▼ Sell | Open Market | 29,971 Shares held | 6/16/2023 | View profile |
| Beetham Thomas W. Chief Operating Officer | ▼ Sell | Tax Withholding | 13,271 Shares held | 3/3/2026 | View profile |
| Harmon Seth Chief Financial Officer | ▼ Sell | Tax Withholding | 7,790 Shares held | 3/3/2026 | View profile |
| Tousignant Jennifer Chief Legal Officer | ▼ Sell | Open Market | 0 Shares held | 8/19/2026 | View profile |
| Katz Barrett Chief Medical Officer | ▼ Sell | Open Market | 0 Shares held | 1/17/2023 | View profile |
Transaction History
| Tousignant Jennifer | ▼ Sell | Open Market | 4,212 | $103K | 8/19/2026 |
| Tousignant Jennifer | ▲ Buy | Option Exercise | 10,000 | $144K | 8/19/2026 |
| Tousignant Jennifer | ▼ Sell | Open Market | 10,000 | $245K | 8/19/2026 |
| Tripuraneni Radhika | ▲ Buy | Option Exercise | 40,000 | $528K | 8/14/2026 |
| Fairmount Funds Management LLC | ▲ Buy | Open Market | 1,176,470 | $20.0M | 5/11/2026 |
| Tousignant Jennifer | ▲ Buy | Option Exercise | 5,169 | — | 3/3/2026 |
| Tousignant Jennifer | ▼ Sell | Tax Withholding | 1,724 | $51K | 3/3/2026 |
| Harmon Seth | ▼ Sell | Tax Withholding | 2,091 | $61K | 3/3/2026 |
| Beetham Thomas W. | ▲ Buy | Option Exercise | 9,409 | — | 3/3/2026 |
| Harmon Seth | ▲ Buy | Option Exercise | 6,267 | — | 3/3/2026 |
| Beetham Thomas W. | ▼ Sell | Tax Withholding | 3,138 | $92K | 3/3/2026 |
| Mahoney Stephen F. | ▲ Buy | Option Exercise | 18,357 | — | 3/3/2026 |
| Mahoney Stephen F. | ▼ Sell | Tax Withholding | 7,627 | $224K | 3/3/2026 |
| Tousignant Jennifer | ▼ Sell | Open Market | 2,272 | $71K | 12/31/2025 |
| Fairmount Funds Management LLC | ▲ Buy | Open Market | 454,545 | $10.0M | 10/23/2025 |
| Fairmount Funds Management LLC | ▲ Buy | Option Exercise | 12,500 | $154K | 6/10/2025 |
| Fairmount Funds Management LLC | ▲ Buy | Option Exercise | 1,600 | $12K | 6/9/2025 |
| Beetham Thomas W. | ▲ Buy | Open Market | 5,000 | $117K | 9/27/2024 |
| Mahoney Stephen F. | ▲ Buy | Open Market | 21,400 | $499K | 9/27/2024 |
| Fairmount Funds Management LLC | ▲ Buy | Open Market | 1,600,000 | $30.0M | 9/13/2024 |
| Fairmount Funds Management LLC | ▼ Sell | Other | 5,859 | — | 3/28/2024 |
| Fairmount Funds Management LLC | ▼ Sell | Other | 5,859 | — | 3/28/2024 |
| Fairmount Funds Management LLC | ▲ Buy | Open Market | 476,190 | $10.0M | 1/22/2024 |
| Meisner Lara | ▲ Buy | Option Exercise | 27 | $622 | 6/16/2023 |
| Meisner Lara | ▼ Sell | Open Market | 27 | $765 | 6/16/2023 |
| Meisner Lara | ▼ Sell | Open Market | 2,269 | $64K | 6/15/2023 |
| Meisner Lara | ▲ Buy | Option Exercise | 2,269 | $52K | 6/15/2023 |
| Meisner Lara | ▲ Buy | Option Exercise | 5,126 | $95K | 6/6/2023 |
| Meisner Lara | ▼ Sell | Open Market | 5,126 | $128K | 6/6/2023 |
| Meisner Lara | ▲ Buy | Option Exercise | 499 | $9K | 6/5/2023 |
| Meisner Lara | ▼ Sell | Open Market | 499 | $12K | 6/5/2023 |
| Meisner Lara | ▲ Buy | Option Exercise | 1,875 | $26K | 6/2/2023 |
| Meisner Lara | ▼ Sell | Open Market | 1,875 | $45K | 6/2/2023 |
| Scott Dunseth Myers | ▲ Buy | Open Market | 4,000 | $101K | 4/12/2023 |
| Scott Dunseth Myers | ▲ Buy | Open Market | 5,500 | $160K | 3/13/2023 |
| Meisner Lara | ▼ Sell | Open Market | 29,971 | $871K | 3/9/2023 |
| Scott Dunseth Myers | ▲ Buy | Grant | 250,000 | $0 | 2/6/2023 |
| Violin Jonathan | ▼ Sell | Open Market | 50,000 | $1.8M | 2/2/2023 |
| Meisner Lara | ▲ Buy | Option Exercise | 4,971 | $114K | 1/23/2023 |
| Meisner Lara | ▲ Buy | Option Exercise | 1,872 | $26K | 1/23/2023 |
| Meisner Lara | ▼ Sell | Open Market | 6,843 | $244K | 1/23/2023 |
| Katz Barrett | ▲ Buy | Option Exercise | 24,853 | $572K | 1/17/2023 |
| Katz Barrett | ▼ Sell | Open Market | 24,853 | $925K | 1/17/2023 |
| Katz Barrett | ▲ Buy | Option Exercise | 4,147 | $96K | 1/13/2023 |
| Katz Barrett | ▼ Sell | Open Market | 4,147 | $153K | 1/13/2023 |
| Katz Barrett | ▼ Sell | Open Market | 47,377 | $1.7M | 1/10/2023 |
| Katz Barrett | ▲ Buy | Option Exercise | 47,377 | $1.1M | 1/10/2023 |
| Katz Barrett | ▲ Buy | Option Exercise | 12,623 | $291K | 1/9/2023 |
| Katz Barrett | ▼ Sell | Open Market | 12,623 | $417K | 1/9/2023 |
| Meisner Lara | ▲ Buy | Option Exercise | 16,326 | $376K | 12/21/2022 |
| Meisner Lara | ▼ Sell | Open Market | 16,326 | $477K | 12/21/2022 |
| Meisner Lara | ▲ Buy | Option Exercise | 600 | $14K | 12/20/2022 |
| Meisner Lara | ▼ Sell | Open Market | 600 | $17K | 12/20/2022 |
| Meisner Lara | ▲ Buy | Option Exercise | 1,297 | $30K | 12/16/2022 |
| Meisner Lara | ▼ Sell | Open Market | 1,297 | $37K | 12/16/2022 |
| Meisner Lara | ▲ Buy | Option Exercise | 300 | $7K | 12/15/2022 |
| Meisner Lara | ▼ Sell | Open Market | 300 | $8K | 12/15/2022 |
| Meisner Lara | ▲ Buy | Option Exercise | 15,656 | $361K | 12/14/2022 |
| Meisner Lara | ▼ Sell | Open Market | 15,656 | $440K | 12/14/2022 |
| Meisner Lara | ▲ Buy | Option Exercise | 600 | $14K | 12/12/2022 |
| Meisner Lara | ▼ Sell | Open Market | 600 | $17K | 12/12/2022 |
| Meisner Lara | ▲ Buy | Option Exercise | 8,125 | $114K | 11/15/2022 |
| Meisner Lara | ▼ Sell | Open Market | 8,125 | $179K | 11/15/2022 |
| Fairmount Funds Management LLC | ▲ Buy | Open Market | 425,531 | $10.0M | 8/17/2022 |
| Violin Jonathan | ▼ Sell | Open Market | 30,000 | $366K | 6/1/2022 |
| Violin Jonathan | ▼ Sell | Open Market | 30,000 | $391K | 5/2/2022 |
| Violin Jonathan | ▼ Sell | Open Market | 3,600 | $68K | 4/4/2022 |
| Violin Jonathan | ▼ Sell | Open Market | 26,400 | $499K | 4/1/2022 |
| Violin Jonathan | ▼ Sell | Open Market | 11,106 | $193K | 3/2/2022 |
| Violin Jonathan | ▼ Sell | Open Market | 18,894 | $337K | 3/1/2022 |
| Violin Jonathan | ▼ Sell | Open Market | 909 | $17K | 2/3/2022 |
| Violin Jonathan | ▼ Sell | Open Market | 12,340 | $228K | 2/2/2022 |
| Violin Jonathan | ▼ Sell | Open Market | 16,751 | $327K | 2/1/2022 |
| Violin Jonathan | ▼ Sell | Other | 627,564 | $0 | 12/8/2021 |
| Frazier Life Sciences Public Fund, L.P. | ▲ Buy | Open Market | 200,000 | $2.2M | 9/23/2021 |
| Fairmount Funds Management LLC | ▲ Buy | Open Market | 909,000 | $10.0M | 9/21/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
VRDN Draws Institutional Interest; Set for Wells Fargo Healthcare Conference
Viridian Therapeutics has attracted attention as a healthcare specialist identified it among four biotech stocks of interest, according to Benzinga. The company is scheduled to present at the Wells Fargo Healthcare Conference, a routine industry event for biotech firms seeking investor engagement. The stock is currently trading within its 52-week range of $13.18 to $34.29, while analysts maintain an average price target of $36.62 based on 16 estimates.
VRDN Draws Institutional Interest; Set for Wells Fargo Healthcare Conference. Viridian Therapeutics has attracted attention as a healthcare specialist identified it among four biotech stocks of interest, according to Benzinga. The company is scheduled to present at the Wells Fargo Healthcare Conference, a routine industry event for biotech firms seeking investor engagement. The stock is currently trading within its 52-week range of $13.18 to $34.29, while analysts maintain an average price target of $36.62 based on 16 estimates.